Dear Reader :
Dear Reader: This month’s edition of Citeline’s newsletter, developed in alliance with the IPA, brings you the important talking points from the recent J.P. Morgan Healthcare Conference, including pricing of Alzheimer’s drugs.
The marquee meeting saw AbbVie CEO Rick Gonzalez reiterate his prediction that the company will weather Humira’s loss of exclusivity and return to growth in 2025, while US FDA Commissioner Robert Califf laid out why he’s opposed to offshoring as a financial arbitrage.
There’s also a must-read piece on key clinical trial readouts to watch out for in 2023.
Anju Ghangurde - Executive Editor (Asia Pacific), Scrip/Pink Sheet
Dr. Shridhar Narayanan - Senior Technical Advisor - Innovation, IPA